Sean E. Aeder

Array ( [id] => 11025506 [patent_doc_number] => 20160222462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'Analysis of Apoptotic Bodies in Bodily Fluids' [patent_app_type] => utility [patent_app_number] => 15/004813 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8164 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15004813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10785499 [patent_doc_number] => 20160131655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'BCMA-BASED STRATIFICATION AND THERAPY FOR MULTIPLE MYELOMA PATIENTS' [patent_app_type] => utility [patent_app_number] => 14/996503 [patent_app_country] => US [patent_app_date] => 2016-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13708 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14996503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350611 [patent_doc_number] => 20160369351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'DETECTION OF CHROMOSOMAL REGION COPY NUMBER CHANGES TO DIAGNOSE MELANOMA' [patent_app_type] => utility [patent_app_number] => 14/994977 [patent_app_country] => US [patent_app_date] => 2016-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 15051 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14994977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353413 [patent_doc_number] => 10793915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Context dependent diagnostics test for guiding cancer treatment [patent_app_type] => utility [patent_app_number] => 15/542520 [patent_app_country] => US [patent_app_date] => 2016-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 25 [patent_no_of_words] => 17950 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15542520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590877 [patent_doc_number] => 20180346987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => RESPONSE TO EGFR BLOCKADE [patent_app_type] => utility [patent_app_number] => 15/541521 [patent_app_country] => US [patent_app_date] => 2016-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15541521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756902 [patent_doc_number] => 10975442 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Molecular biomarkers for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 15/537839 [patent_app_country] => US [patent_app_date] => 2015-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 156 [patent_figures_cnt] => 86 [patent_no_of_words] => 71289 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15537839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10769068 [patent_doc_number] => 20160115224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'FORM-SPECIFIC ANTIBODIES FOR NAG-1 (MIC-1, GDF-15), H6D AND OTHER TGF-BETA SUBFAMILY AND HEART DISEASE AND CANCER DIAGNOSES' [patent_app_type] => utility [patent_app_number] => 14/966371 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11509 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14966371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353141 [patent_doc_number] => 10793642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Binding members for human c-MAF [patent_app_type] => utility [patent_app_number] => 15/534893 [patent_app_country] => US [patent_app_date] => 2015-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 29154 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15534893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13705353 [patent_doc_number] => 20170363631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => PLASMA AUTOANTIBODY BIOMARKERS FOR BASAL LIKE BREAST CANCER [patent_app_type] => utility [patent_app_number] => 15/534203 [patent_app_country] => US [patent_app_date] => 2015-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15534203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11987793 [patent_doc_number] => 20170291948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'ANTIBODY BINDING TO NEUROPILIN 1 AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/532078 [patent_app_country] => US [patent_app_date] => 2015-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 12057 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15532078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13691921 [patent_doc_number] => 20170356915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => BLADDER CANCER PROGNOSIS [patent_app_type] => utility [patent_app_number] => 15/529937 [patent_app_country] => US [patent_app_date] => 2015-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15529937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980025 [patent_doc_number] => 20160176969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'HETERODIMERIC ANTIBODIES INCLUDING BINDING TO CD8' [patent_app_type] => utility [patent_app_number] => 14/952705 [patent_app_country] => US [patent_app_date] => 2015-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 67 [patent_no_of_words] => 28465 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14952705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16564293 [patent_doc_number] => 10889653 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-12 [patent_title] => Heterodimeric antibodies that bind CD3 and tumor antigens [patent_app_type] => utility [patent_app_number] => 14/952714 [patent_app_country] => US [patent_app_date] => 2015-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 192 [patent_figures_cnt] => 190 [patent_no_of_words] => 25098 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14952714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15355633 [patent_doc_number] => 10526417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Heterodimeric antibodies that bind CD3 and CD38 [patent_app_type] => utility [patent_app_number] => 14/952786 [patent_app_country] => US [patent_app_date] => 2015-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 109 [patent_no_of_words] => 22126 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14952786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16230770 [patent_doc_number] => 10738310 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-11 [patent_title] => Treating cancer deficient in FANCA, FANCD2, FANCE, or FANCG with an ATM inhibitor [patent_app_type] => utility [patent_app_number] => 14/948914 [patent_app_country] => US [patent_app_date] => 2015-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 104 [patent_no_of_words] => 25227 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14948914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10722452 [patent_doc_number] => 20160068599 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-10 [patent_title] => 'METHOD FOR TREATING NEUROENDOCRINE CANCER' [patent_app_type] => utility [patent_app_number] => 14/945831 [patent_app_country] => US [patent_app_date] => 2015-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 16129 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14945831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11090668 [patent_doc_number] => 20160287635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS' [patent_app_type] => utility [patent_app_number] => 14/942337 [patent_app_country] => US [patent_app_date] => 2015-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 37826 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14942337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799537 [patent_doc_number] => 20160145693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS' [patent_app_type] => utility [patent_app_number] => 14/940614 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 78093 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784209 [patent_doc_number] => 20160130365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'Methods and compositions for prognosis, diagnosis, and treatment of ADAM8-expressing cancer' [patent_app_type] => utility [patent_app_number] => 14/940344 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 24390 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11809090 [patent_doc_number] => 09713648 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-25 [patent_title] => 'Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates' [patent_app_type] => utility [patent_app_number] => 14/938658 [patent_app_country] => US [patent_app_date] => 2015-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 16168 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14938658 [rel_patent_id] =>[rel_patent_doc_number] =>)